• Users Online: 231
  • Print this page
  • Email this page
Year : 2022  |  Volume : 60  |  Issue : 2  |  Page : 142-146

Role of trans-scleral diode cyclophotocoagulation in refractory glaucoma: A large retrospective study

Department of Glaucoma, at Aravind Eye Hospital, Madurai, Tamil Nadu, India

Correspondence Address:
Vidya Raja
Glaucoma Consultant, Department of Glaucoma Services, Aravind Eye Hospital, Madurai - 625 020, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjosr.tjosr_27_22

Rights and Permissions

Purpose: To study the efficacy and safety of Trans-scleral Cyclophotocoagulation (TS-CPC) to achieve adequate IOP reduction and a comfortable eye in refractory glaucoma. Material and Methods: The study was conducted at the glaucoma clinic of Aravind Eye Hospital, Madurai (TN). A total of 391 eyes of 317 patients treated from January 2019 – December 2019 with a minimum of 6 months and maximum follow-up up to 1 year were included in the study. Results: The Mean Pre-treatment IOP was 44.01 ± 14.06 mmHg. Mean post-treatment IOP at 1, 3, 6 months and up-to 1 year was 27.09 ± 14.07 mmHg, 22.65 ± 16.95 mmHg, 22.97 ± 16.60 and 22.88 ± 17.03mmHg, respectively. Complications encountered were pain and hypotony (1.7%). Conclusion: With the highest number of cases so far and with a longer follow-up period, we found that Trans-scleral Diode Cyclophotocoagulation is highly effective in lowering intraocular pressure. High success rate and low complication rate combined with portability, durability, and easy to learn technique make this procedure the treatment of choice for refractory and complex glaucoma.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded81    
    Comments [Add]    

Recommend this journal